Summary
- Q4 2018 results included 7% y/y revenue growth and 33% EPS growth.
- 2019 outlook more about trial results than drug approvals or revenue growth.
- Effects of the Tecfidera ruling are exaggerated.
Biogen (BIIB) has long been one of the premier biotechnology companies. In the past, most of its income has come from multiple sclerosis treatments, but it is transitioning to treating multiple neurological diseases. To give a first impression of its ability to grow, consider that revenue in 2013 was $6.93 billion. That increased 94% to $13.45 billion in 2018.
I am optimistic about Biogen's development in 2019. I recently wrote about growth prospects for the next decade in Biogen Outlook for the 2020s. In this report, I will focus on the outlook for 2019.
Biogen Stock Price
Biogen's 52-week high was $388.67, set last July on a moment of Alzheimer's disease therapy optimism. Its low of $249.17 was last April, and it had a pretty rough December, along with most other biotech stocks.

